BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33485349)

  • 1. HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia.
    Guo C; Gao YY; Ju QQ; Zhang CX; Gong M; Li ZL
    J Transl Med; 2021 Jan; 19(1):42. PubMed ID: 33485349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
    Li FJ; Ding S; Pan J; Shakhmatov MA; Kashentseva E; Wu J; Li Y; Soong SJ; Chiorazzi N; Davis RS
    Blood; 2008 Jul; 112(1):179-87. PubMed ID: 18314442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
    Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
    Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
    Morabito F; Cutrona G; Mosca L; D'Anca M; Matis S; Gentile M; Vigna E; Colombo M; Recchia AG; Bossio S; De Stefano L; Maura F; Manzoni M; Ilariucci F; Consoli U; Vincelli I; Musolino C; Cortelezzi A; Molica S; Ferrarini M; Neri A
    Leuk Res; 2015 Aug; 39(8):840-5. PubMed ID: 26038121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
    Molica S; Giannarelli D; Levato L; Gentile M; Mirabelli R; Morabito F
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e55-60. PubMed ID: 25445470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EXPRESSION OF LIPOPROTEIN LIPASE AND c-MYC ONCOGENE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AFFECTED BY THE CHORNOBYL ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Diagil IS; Martina ZV
    Probl Radiac Med Radiobiol; 2020 Dec; 25():421-429. PubMed ID: 33361851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
    Balakrishna J; Basumallik N; Matulonis R; Scott D; Salem D; Jasper G; Wiestner A; Stetler-Stevenson M; Marti G; Sun C; Yuan CM
    Leuk Lymphoma; 2021 Aug; 62(8):1828-1839. PubMed ID: 33734005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia.
    Hojjat-Farsangi M; Jeddi-Tehrani M; Razavi SM; Sharifian RA; Mellstedt H; Shokri F; Rabbani H
    Cancer Sci; 2009 Dec; 100(12):2346-53. PubMed ID: 19824994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Abramenko I; Bilous N; Chumak A; Kryachok I; Fedorenko Z; Martina Z; Dyagil I
    Leuk Res; 2021 Nov; 110():106686. PubMed ID: 34492598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
    Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
    Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
    Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
    Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?
    Rozovski U; Keating MJ; Estrov Z
    Acta Haematol; 2018; 140(1):51-54. PubMed ID: 30114695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The
    Perez-Chacon G; Zapata JM
    Front Immunol; 2021; 12():627602. PubMed ID: 33912159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the prognosis of early stage chronic lymphocytic leukaemia patients.
    Pepper C; Majid A; Lin TT; Hewamana S; Pratt G; Walewska R; Gesk S; Siebert R; Wagner S; Kennedy B; Miall F; Davis ZA; Tracy I; Gardiner AC; Brennan P; Hills RK; Dyer MJ; Oscier D; Fegan C
    Br J Haematol; 2012 Feb; 156(4):499-507. PubMed ID: 22171799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptomics-based validation of the relatedness of heterogeneous nuclear ribonucleoproteins to chronic lymphocytic leukemia as potential biomarkers of the disease aggressiveness.
    Alsagaby SA
    Saudi Med J; 2019 Apr; 40(4):328-338. PubMed ID: 30957125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study.
    Stamatopoulos B; Smith T; Crompot E; Pieters K; Clifford R; Mraz M; Robbe P; Burns A; Timbs A; Bruce D; Hillmen P; Meuleman N; Mineur P; Firescu R; Maerevoet M; De Wilde V; Efira A; Philippé J; Verhasselt B; Offner F; Sims D; Heger A; Dreau H; Schuh A
    Clin Cancer Res; 2018 Oct; 24(20):5048-5057. PubMed ID: 29945996
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of Cytogenetics Aberrations and
    Muñoz-Novas C; González-Gascón-Y-Marín I; Figueroa I; Sánchez-Paz L; Pérez-Carretero C; Quijada-Álamo M; Rodríguez-Vicente AE; Infante MS; Foncillas MÁ; Landete E; Churruca J; Marín K; Ramos V; Sánchez Salto A; Hernández-Rivas JÁ
    Glob Med Genet; 2024 Jan; 11(1):59-68. PubMed ID: 38348157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
    Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
    Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
    Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
    Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
    Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
    Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.